Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism

Lipids in Health and Disease

Research

Hua Xiang¹  Wei Zhao¹  Xiao-Bo Li²  Hong Shen³  Yao Yao³  Hong Xiao³  Yan-Yan Zeng³ 

[1] Department of Medical Chemistry, China Pharmaceutical University, 210009, Nanjing, PR China;Department of Pharmacy English, China Pharmaceutical University, 210009, Nanjing, PR China;Nanjing Brain Hospital affiliated to Nanjing Medical University, 210029, Nanjing, PR China;

关键词: High Density Lipoprotein Cholesterol;    Model Group;    Orlistat;    High Dosage Group;    Rimonabant;   

DOI  :  10.1186/1476-511X-9-49

 received in 2010-03-11, accepted in 2010-05-19,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundThe novel compound 1a is one of the isoflavone fatty acid esters. In order to investigate the anti-obesity effect of compound 1a and its potential mechanism of influence in adipocyte differentiation, Obese male C57BL/6J mice induced by high-fat diet (HFD) and rat preadipocytes (3T3-L1 cell) were used.MethodsAfter 4-week HFD induction, the obese model was made successfully. After treatment with compound 1a, mice plasma biochemistry parameters were analyzed. In addition, mice hepatic tissue slice was observed. In in vitro research, 3T3-L1 cell differentiation by Oil-Red-O staining and adipocyte apoptosis was detected by flow cytometry.ResultsThe in vivo results implied that compound 1a significantly decreased the body weight, white adipose tissue weight of obesity mice(p < 0.05), reduced leptin and TG in plasma(p < 0.05), elevated HDL-C in serum(p < 0.05). The in vitro results suggested that compound 1a could significantly suppress the adipocyte viability and lipid accumulation in the differentiation of preadipocyte, and induce apoptosis in both preadipocytes and mature adipocytes(p < 0.05).ConclusionCompound 1a regulates serum lipid profiles, decreases adipose tissue mass and body weight gain by inducing adipocyte apoptosis in high fat diet induced mice. Thus, it may be used to treat obese patients with hypercholesterolemia and hypertriglyceridemia.

【 授权许可】

Unknown   
© Yao et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.